Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
İçerik Proactive Investors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Proactive Investors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Player FM - Podcast Uygulaması
Player FM uygulamasıyla çevrimdışı Player FM !
Player FM uygulamasıyla çevrimdışı Player FM !
Lumos Diagnostics CEO on 2024 milestones and 2025 goals
MP3•Bölüm sayfası
Manage episode 456606021 series 2891889
İçerik Proactive Investors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Proactive Investors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) CEO Doug Ward takes Proactive's Stephen Gunnion through the company's achievements in 2024 and plans for the year ahead. Ward highlighted several key milestones, including the signing of a strategic partnership with Hologic and progress with its flagship products, ViraDx and FebriDx. He emphasised that FebriDx is transforming treatment by differentiating between bacterial and viral infections, helping to combat antibiotic resistance. Ward also discussed Lumos’s collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which funded a clinical trial to expand FebriDx's accessibility. He noted, “This is a huge win for Lumos, enabling us to go from 18,000 locations to 220,000 locations in the US with CLIA waivers.” Furthermore, the company successfully secured A$10.00 million in funding, attracting key investors like Tenmile and Ryder Capital. Ward expressed optimism for 2025, focusing on revenue growth, the BARDA-funded trial, and enhancing their partnerships. Visit Proactive’s YouTube channel for more insightful interviews. Don’t forget to like, subscribe, and enable notifications for future updates! #LumosDiagnostics #FebriDx #DiagnosticInnovation #AntibioticStewardship #HealthcareSolutions #HologicPartnership #BARDA #PointOfCareTesting #MedicalDevices InvestmentNews #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 bölüm
MP3•Bölüm sayfası
Manage episode 456606021 series 2891889
İçerik Proactive Investors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Proactive Investors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) CEO Doug Ward takes Proactive's Stephen Gunnion through the company's achievements in 2024 and plans for the year ahead. Ward highlighted several key milestones, including the signing of a strategic partnership with Hologic and progress with its flagship products, ViraDx and FebriDx. He emphasised that FebriDx is transforming treatment by differentiating between bacterial and viral infections, helping to combat antibiotic resistance. Ward also discussed Lumos’s collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which funded a clinical trial to expand FebriDx's accessibility. He noted, “This is a huge win for Lumos, enabling us to go from 18,000 locations to 220,000 locations in the US with CLIA waivers.” Furthermore, the company successfully secured A$10.00 million in funding, attracting key investors like Tenmile and Ryder Capital. Ward expressed optimism for 2025, focusing on revenue growth, the BARDA-funded trial, and enhancing their partnerships. Visit Proactive’s YouTube channel for more insightful interviews. Don’t forget to like, subscribe, and enable notifications for future updates! #LumosDiagnostics #FebriDx #DiagnosticInnovation #AntibioticStewardship #HealthcareSolutions #HologicPartnership #BARDA #PointOfCareTesting #MedicalDevices InvestmentNews #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 bölüm
Все серии
×Player FM'e Hoş Geldiniz!
Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.